Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420

Benzinga · 2d ago
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $418 to $420.